Seladelpar

Seladelpar (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. The drug completed a phase II trial for primary biliary cholangitis. "Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus." A phase III trial in patients with PBC also found reduced pruritus and improved liver biochemistry, despite being terminated early.

See also

• Elafibranor
• GW501516
• Peroxisome proliferator-activated receptor

References

External links

• Seladelpar - AdisInsight

1. Ibuprofen
2. Berberine
3. Primary biliary cholangitis
4. Elafibranor
5. Perfluorooctanoic acid
6. GW501516
7. Pioglitazone
8. Fenofibrate
9. Thiazolidinedione
10. Fibrate
11. Telmisartan
12. Saroglitazar
13. Palmitoylethanolamide
14. PPAR agonist
15. Gemfibrozil
16. Peroxisome proliferator-activated receptor
17. GW0742
18. Genistein
19. Bezafibrate
20. Arachidonic acid